John L Kulp

Dr. John L Kulp

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2010 in Langmuir
Verified
Journal Article
Closed access
DBDaniel E. Barlow
Daniel E. Barlow
Gary H. DickinsonGary H. Dickinson
Gary H. Dickinson
BOBeatriz Orihuela
Beatriz Orihuela
JKJohn L Kulp
John L Kulp
DRDaniel Rittschof
Daniel Rittschof
KWKathryn J. Wahl
Kathryn J. Wahl

27 June 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DWDeyun Wang
Deyun Wang
KCKang Chen
Kang Chen
JKJohn L Kulp
John L Kulp
PAParamjit S. Arora
Paramjit S. Arora

26 August 2004 in Langmuir
Verified
Journal Article
Closed access
DKDaisuke Kase
Daisuke Kase
JKJohn L Kulp
John L Kulp
MYMasako Yudasaka
Masako Yudasaka
JEJohn Spencer Evans
John Spencer Evans
SISumio Iijima
Sumio Iijima
KSKiyotaka Shiba
Kiyotaka Shiba

13 May 2009 in ACS Nano
Verified
Journal Article
Closed access
CSChristopher R. So
Christopher R. So
JKJohn L Kulp
John L Kulp
EOErsin Emre Oren
Ersin Emre Oren
HZHadi Zareie
Hadi Zareie
Candan TamerlerCandan Tamerler
Candan Tamerler
MSMehmet Sarikaya
Mehmet Sarikaya

1 November 2017 in Antiviral Research
Verified
Journal Article
Closed access
BLBowei Liu
Bowei Liu
LTLiudi Tang
Liudi Tang
XZXiaohui Zhang
Xiaohui Zhang
JMJulia Ma
Julia Ma
MSMohit Sehgal
Mohit Sehgal
JCJinhong Chang
Jinhong Chang

1 December 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
FGFang Guo
Fang Guo
SWShuo Wu
Shuo Wu
JJJustin Julander
Justin Julander
JMJulia Ma
Julia Ma
XZXuexiang Zhang
Xuexiang Zhang
JCJinhong Chang
Jinhong Chang
Although a highly effective vaccine is available, the number of yellow fever cases has increased over the past 2 decades, which highlights the pressing need for antiviral therapeutics. In a high-throughput screening campaign, we identified an acetic acid benzodiazepine (BDAA) compound which potently inhibits yellow fever virus (YFV). Interestingly, while treatment of YFV-infected cultures with 2 μM BDAA reduced the virion production by greater than 2 logs, the compound was not active against 21 other viruses from 14 different viral families. Selection and genetic analysis of drug-resistant viruses revealed that replacement of the proline at amino acid 219 (P219) of the nonstructural protein 4B (NS4B) with serine, threonine, or alanine conferred YFV with resistance to BDAA without apparent loss of replication fitness in cultured mammalian cells. However, replacement of P219 with glycine conferred BDAA resistance with significant loss of replication ability. Bioinformatics analysis predicts that the P219 amino acid is localized at the endoplasmic reticulum lumen side of the fifth putative transmembrane domain of NS4B, and the mutation may render the viral protein incapable of interacting with BDAA. Our studies thus revealed an important role and the structural basis for the NS4B protein in supporting YFV replication. Moreover, in YFV-infected hamsters, oral administration of BDAA protected 90% of the animals from death, significantly reduced viral load by greater than 2 logs, and attenuated virus infection-induced liver injury and body weight loss. The encouraging preclinical results thus warrant further development of BDAA or its derivatives as antiviral agents to treat yellow fever. IMPORTANCE Yellow fever is an acute viral hemorrhagic disease which threatens approximately 1 billion people living in tropical areas of Africa and Latin America. Although a highly effective yellow fever vaccine has been available for more than 7 decades, the low vaccination rate fails to prevent outbreaks in at-risk regions. It has been estimated that up to 1.7 million YFV infections occur in Africa each year, resulting in 29,000 to 60,000 deaths. Thus far, there is no specific antiviral treatment for yellow fever. To cope with this medical challenge, we identified a benzodiazepine compound that selectively inhibits YFV by targeting the viral NS4B protein. To our knowledge, this is the first report demonstrating in vivo safety and antiviral efficacy of a YFV NS4B inhibitor in an animal model. We have thus reached a critical milestone toward the development of specific antiviral therapeutics for clinical management of yellow fever.